Infectious Diseases in Critical Care Medicine

(ff) #1
commonly due to vascular access lines. Gram-positive cocci including methicillin-
resistant coagulase-negative staphylococci (MRSE), MRSA, gram-negative rods, and
yeasts (notably,Candidaspp.) are the usual culprits.


  1. The severity of the patient’s underlying illness: Studies in the older literature classified
    patients’ underlying illnesses as “rapidly fatal” (that is, likely to result in death
    during the present hospitalization), “ultimately fatal” (that is, likely to result in death
    within 5 years), and “nonfatal.” Dating to the landmark 1962 paper by McCabe and
    Jackson, such studies demonstrated a powerful effect of underlying illness on
    mortality rates, especially from sepsis due to gram-negative bacilli (16). More recent
    studies extend those observations using newer tools, notably the APACHE II and
    SOFA scoring systems for disease severity (17). The take-home point is that one
    should err toward broader-spectrum empiric therapy for patients with serious
    underlying diseases on account of the smaller margin for error.

  2. Local epidemiology and antibiotic susceptibility data: There are data to indicate that
    prescribing by an “on-call” infectious diseases specialist correlates with appropriate
    prescribing (in one study, 78% vs. 54% for other physicians) and improved survival
    (18). Infectious diseases specialists presumably performed better by dint of greater
    awareness of the most likely pathogens and their susceptibilities. The question arises
    whether this benefit might likewise be achieved through greater awareness of local
    epidemiology and antimicrobial susceptibility data, informed by knowledge of the
    most likely pathogens for this or that disease syndrome. Such local data on resistant
    pathogens is now being taken into account in computer-based prescribing tools
    tailored to individual hospitals and ICUs. Even traditional workhorses such as
    piperacillin/tazobactam and to some extent the carbapenems are now facing
    resistant bacteria. In a recent article from France, 16% ofE. coliisolates from
    clinically relevant specimens were resistant or intermediate to pip/tazo (10). High-
    level penicillinase production was the main mechanism of resistance, and prior
    amoxicillin therapy was a risk factor.
    Trouillet et al. identified the following significant independent factors for
    piperacillin-resistant VAP: presence of an underlying fatal medical condition,
    previous fluoroquinolone use, and initial disease severity (19). The antimicrobial
    resistance rates among gram-negative bacilli in ICUs across the United States were
    evaluated in a Merck-sponsored database. During the 12-year period from 1993 to
    2004, 74,394 gram-negative bacillus isolates were evaluated. The organisms most
    frequently isolated wereP. aeruginosa(22.2%),E. coli(18.8%),Enterobacter cloacae
    (9.1%),Acinetobacterspp. (6.2%), andSerratia(5.5%). The investigators found a greater
    than fourfold increase in the prevalence of multidrug resistance (defined as
    resistance to at least one extended-spectrum cephalosporin, one aminoglycoside
    and ciprofloxacin) forP. aeruginosaandAcinetobacterspp. (20).

  3. Cost: Cost becomes a relatively minor consideration when a patient’s life is at stake.
    Moreover, the cost of antimicrobial agents is relatively minor compared to the cost of
    other modalities (including newer biological agents such as activated protein C) and
    the total cost of ICU stay. Nevertheless, the cost of antimicrobial therapy is far from
    trivial and, moreover, newer agents can be extremely expensive compared with the
    tried-and-true old standbys. Examples include the cost of linezolid or daptomycin
    versus generic vancomycin for MRSA and MRSE infections and the cost of lipid
    formulations of amphotericin B versus amphotericin B deoxycholate. It therefore
    behooves prescribing physicians to be broadly familiar with which agents are the
    most cost-effective. Many hospitals provide this information in a general way (e.g., $,
    $$, $$$, or $$$$), since indicating the exact cost presents problems for both the
    hospital and the prescriber.


DE-ESCALATION: LIMITING THE DURATION OF BROAD-SPECTRUM THERAPY
Except in the direst emergencies, appropriate specimens should be obtained for cultures before
instituting empiric antimicrobial therapy. While a thorough discussion of appropriate


Selection of Antibiotics in Critical Care 491

Free download pdf